Cargando…
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
BACKGROUND: Thalidomide has potent anti-inflammatory and anti-angiogenic properties. It was evaluated in combination with chemotherapy in two randomised placebo-controlled trials in patients with small cell lung cancer (SCLC, n=724) and advanced non-small cell lung cancer (NSCLC, n=722). Neither stu...
Autores principales: | Young, R J, Tin, A W, Brown, N J, Jitlal, M, Lee, S M, Woll, P J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304418/ https://www.ncbi.nlm.nih.gov/pubmed/22353811 http://dx.doi.org/10.1038/bjc.2012.50 |
Ejemplares similares
-
The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006) -
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
por: Oikonomopoulou, K, et al.
Publicado: (2008) -
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
por: Pommier, A J C, et al.
Publicado: (2014) -
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015) -
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)